New Pathway for Reducing the Severity of Rheumatoid Arthritis Symptoms

Article

Compound shows promise in reducing a precursor to RA.

Compound shows promise in reducing a precursor to RA.

Researchers have identified a novel chemical compound that can reduce the severity of rheumatoid arthritis (RA), according to a study published in the Journal of Pharmacology and Experimental Therapeutics (JPET).

Researchers from Montana State University built on prior studies which had identified the chemical compound, called IQ 1S, in order to evaluate its effects on RA. The Montana research team had identified the compound, as well as the independent discoveries elsewhere.

Biologics, types of drugs that treat RA, are developed from genetically engineered proteins or antibodies that can act on substances in the immune system. When these biologics, such as Enbrel and Humira, are used in the treatment of RA, the university press release explained, they are designed to interrupt inflammatory processes that are the hallmark of RA.

“There is a real need to develop new kinds of drugs that are different,” senior author Mark Quinn, PhD, explained in the statement.

He also mentioned that other problems with biologics include their cost and the fact that sometimes a patient will only respond to the biologics for a short period of time, then stop responding.

“They could be combined with other available drugs or replace drugs that aren’t working for patients," Dr. Quinn added.

The researchers observed the chemical compound’s ability to reduce the severity of collagen-induced arthritis, which is a precursor to RA. The compound also demonstrated a capability to inhibit the destruction of cartilage and bone.

The investigators wrote that the compound was effective because it targeted kinase proteins that release activation signals to destructive and inflammatory cells. The IQ 1S compound inhibited the kinase activities, which limited inflammation in joint tissue and lymph node cells, the authors explained.

“IQ 1S can reduce inflammation and cartilage loss associated with collagen induced arthritis and can serve as a small molecule modulator for mechanistic studies of c Jun N terminal kinases function in RA,” the authors concluded.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.